Clinical Trial Update: Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating vandetanib with carboplatin and paclitaxel for resectable stage I–III non-small cell lung cancer was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Vandetanib (vandetanib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-12-07